Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion

Blood

Volumn 90, Issue 4, 1997, Pages 1600-1610

  Huang, Steve ^a   Apasov, Sergey ^a   Koshiba, Masahiro ^a   Sitkovsky, Michail ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOTOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0030878807     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.4.1600     Document Type: Article

References (40)

1. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ: Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2:1067, 1972
2. Kellems RE, Yeung C-Y, lngolia DE: Adenosine deaminase deficiency and severe combined immunodeficiencies. Trends Genet 1:278, 1985
3. Apasov S, Koshiba M, Redegeld F, Sitkovsky M: Role of extracellular ATP and P1 and P2 classes of purinergic receptors in T-cell development and cytotoxic T lymphocyte effector functions. Immunol Rev 146:5, 1995
4. Cronstein BN, Naime D, Firestein G: The antiinflamatory effects of adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 38:1040, 1995
5. Cronstein BN: A novel approach to the development of antiinflammatory agents: Adenosine release at the inflamed sites. J Invest Med 43:50, 1995
6. Olah ME, Stiles GL: Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35:581, 1995
7. Mizumura T, Auchampach JA, Linden J, Bruns RF, Gross GJ: PD81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ Res 4:415, 1996
8. Jacobson KA, van Galen PJM, Williams M: Perspective, adenosine receptors: Pharmacology, structure activity relationships and therapeutic potential. J Med Chem 35:407, 1992
9. Hirschhorn R: Adenosine deaminase deficiency: Molecular basis and recent developments. Clin Immunol Immunopathol 76:S2I9, 1995
10. Hershfield MS, Mitchell BS: Immunodeficiency Diseases Caused by Adenosine Deaminase Deficiency and Purine Nucleoside Phosphorylase Deficiency. New York, NY, McGraw-Hill, 1995
11. Hoskin DW, Reynolds T, Blay J: Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. Int J Cancer 59:854, 1994
12. Blackburn MR, Datta SK, Wakamiya M, Vartabedian BS, Kellems RE: Metabolic and immunologie consequences of limited adenosine deaminase expression in mice. J Biol Chem 271:15203, 1996
13. Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86:147, 1996
14. Carson DA, Kaye J, Wasson DB: The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts. J Immunol 126:348, 1981
15. Ullman B, Levinson BB, Hershfield MS, Martin DW: A biochemical genetic study of the role of specific nucleoside kinases in deoxyadenosine phosphorylation by cultured human cells. J Biol Chem 256:848, 1981
16. Kohn DB, Weinberg KI: Adenosine Deaminase Deficiency. The Genes of Primary Immunodeficiency-Windows on the Immune System and Prospects for Gene Therapy. Bethesda, MD, National Institutes of Health, 1996, p 7
17. + T cells from T cell receptor transgenic mice. J Exp Med 176:1091, 1992
18. + lineage of B lymphocyte differentiation. J Immunol 133:744, 1984
19. Leo O, Foo M, Sachs DH: Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 84:1374, 1987
20. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13:795, 1992
21. Ullman B, Cohen A, Martin DW: Characterization of a cell culture model for the study of adenosine deaminase- and purine nucleoside phosphorylase-deficient immunologic disease. Cell 9:205, 1976
22. Hall JG, Gyure L, Peppard J, Orlans E: Levels of adenosine deaminase in some experimental animal tumours and the possible therapeutic effect of the ADA inhibitor 2-deoxy-coformycin. Br J Cancer 40:750, 1979
23. Waldmann TA: The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232:727, 1986
24. Crabtree GR: Contingent genetic regulatory events in T lymphocyte activation. Science 243:355, 1989
25. Mathôt R, Gubbens-Stibbe JM, Soudijn W, Jacobson KA, Izerman AP, Danhof M: Quantification of the in vivo potency of the adenosine A2a receptor antagonist 8-(3-chlorostyryl) caffeine (CSC). J Pharm Exp Ther 275:245, 1995
26. Green H, Chan T: Pyrimidine starvation induced by adenosine in fibroblasts and lymphoid cells: Role of adenosine deaminase. Science 182:836, 1973
27. Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB: Adenosine receptor ligands: Differences with acute versus chronic treatment. Trends Pharmacol Sci 17:108, 1996
28. Anastassiou ED, Pallogianni F, Balow JP, Yamada H, Boumpas DT: Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R α gene expression at multiple levels. J Immunol 148:2845, 1992
29. Wolberg G, Zimmerman TP, Hiemstra K, Winston M, Chu LC: Adenosine inhibition of lymphocyte-mediated cytolysis: Possible role of cyclic adenosine monophosphate. Science 187:957. 1975
30. Hirschhorn R, Grossman J, Weissmann G: Effect of cyclic 3′-5′ adenosine monophosphate and theophylline on lymphocyte transformation. Proc Soc Exp Biol Med 133:1361, 1970
31. Smith JW, Steiner AL, Parker CW: Human lymphocytic metabolism. Effects of cyclic and noncyclic nucleotides on stimulation by phytohemagglutinin. J Clin Invest 50:442, 1971
32. Zenser TV: Formation of adenosine 3′,5′-monophosphate from adenosine in mouse thymocytes. Biochim Biophys Acta 404:202, 1975
33. Zenser TV, Metzger JF: Comparison of the action of Escherichia coli enterotoxin on the thymocyte adenylate cyclase-cyclic adenosine monophosphate system to that of cholera toxin and prostaglandin E1. Infect Immun 10:503, 1974
34. 3H]-CGS 21680C, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther 251:888-893, 1989
35. Rosen FS, Cooper MD, Wedgwood RJP: The primary immunodeficiencies. N Engl J Med 333:431, 1995
36. Kizaki H, Suzuki K, Tadakuma T, Ishimura Y: Adenosine receptor-mediated accumulation of cyclic AMP-induced T lymphocyte death through internucleosomal DNA cleavage. J Biol Chem 265:5280, 1990
37. McConkey DJ, Orrenius S, Jondal M: Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. J Immunol 145:1227, 1990
38. Lalli E, Sassone-Corsi P, Ceredig R: Block of T lymphocyte differentiation by activation of the cAMP-dependent signal transduction pathway. EMBO J 15:528, 1996
39. van der Kraan PM, van Zandvoort PM, De Abreu RA, van Baal JM, Bakkeren AAJM: Inhibition of lymphoid cell growth by adenine ribonucleotide accumulation. The role of phosphoribosylpy-rophosphate-depletion induced pyrimidine starvation. Biochim Biophys Acta 927:213, 1987
40. Koshiba M, Apasov S, Sverdlov V, Chen P, Erb L, Weisman GA, Turner JT, Sitkovsky MV: Transient up-regulation of P2Y2 nucleotide receptor mRNA expression is an immediate-early gene response in activated thymocytes. Proc Natl Acad Sci USA 94:831, 1997